Use of sterile syringes and aseptic drug preparation are important components of HIV prevention among injection drug users

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue SUPPL., 1998, Pages

  Jones, T Stephen ^a   Vlahov, David ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASEPSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; SYRINGE; VIRUS TRANSMISSION;

DRUG COMPOUNDING; HIV INFECTIONS; HUMANS; NEEDLE SHARING; STERILIZATION; SUBSTANCE ABUSE, INTRAVENOUS; SYRINGES; UNITED STATES; UNITED STATES PUBLIC HEALTH SERVICE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032125404     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199802001-00002     Document Type: Review

References (40)

1. United States Public Health Service. HIV prevention bulletin: medical advice for persons who inject illicit drugs. Atlanta, GA: Centers for Disease Control and Prevention, May 9, 1997.
2. Marmor M, Des Jarlais DC, Cohen H, et al. Risk factors for human immunodeficiency virus among intravenous drug abusers in New York City. AIDS 1987;1:39-44.
3. Chaisson RE, Moss AR, Onishi R, et al. Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am J Public Health 1987;77:169-72.
4. Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for HIV-1 infection in intravenous drug abusers. N Engl J Med 1989; 321:874-9.
5. Centers for Disease Control and Prevention. AIDS associated with injecting-drug use - United States, 1995. MMWR 1996;45:392-8.
6. Vlahov D, Munoz A, Anthony JC, et al. Association of drug injection patterns with antibody to human immunodeficiency virus type 1 among intravenous drug users in Baltimore. Am J Epidemiol 1990;132:847-56.
7. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S6-10.
8. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S11-9.
9. McCoy CB, Metsch LR, Chitwood DD, Shapshak P, Comerford ST. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S25-9.
10. Koester SK. Following the blood: syringe reuse leads to blood-borne virus transmission among injection drug users [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S139-40.
11. Gostin LO, Lazzarini Z, Jones TS, Flaherty K. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users: a national survey on the regulation of syringes and needles. JAMA 1997;277:53-62.
12. Rich JD, Dickinson BP, Case P, et al. Strict syringe laws in Rhode Island are associated with high rates of reusing syringes and HIV risks among injection drug users [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S140-1.
13. Koester SK. Copping, running, and paraphernalia laws; contextual and needle risk behavior among injection drug users in Denver. Human Organization 1994;53:287-95.
14. Case P, Meehan T, Jones TS. Arrests and incarceration of injection drug users for syringe possession in Massachusetts: implications for HIV prevention. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S71-5.
15. Gostin LO. The legal environment impeding access to sterile syringes and needles: the conflict between law enforcement and public health. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S60-70.
16. Lazzarini Z, Schoenbaum EE, O'Neill CH. In New York City, syringe laws and regulations deter physicians and pharmacists from prescribing and selling syringes to persons who may be injection drug users [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S140-1.
17. Morse LJ. Deregulation of syringes and needles for medical use and to prevent the spread of blood-borne pathogens among illicit intravenous drug users [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S143-4.
18. Gershon RRM. Infection control basis for recommending one-time use of sterile syringes and aseptic procedures for injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1):S20-4.
19. Des Jarlais DC. "Single-use" needles and syringes for the prevention of HIV infection among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S52-6.
20. Lurie P, Jones TS, Foley J. A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution? J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S126-32.
21. Lurie P, Reingold AL, Bowser B, et al. The public health impact of needle exchange programs in the United States and abroad, vol 1. San Francisco, University of California, 1993.
22. Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: National Academy Press, 1995.
23. Heimer R, Khoshnood K, Bigg D, Guydish J. Syringe use and reuse: effects of needle exchange programs in three cities. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S37-44.
24. Gleghorn AA, Wright-De Aguero L, Flynn C. Feasibility of one-time use of sterile syringes: a study of active injection drug users in seven United States metropolitan areas. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S30-6.
25. Remis RS, Bruneau J, Hankins CA. Enough sterile syringes to prevent HIV transmission among injection drug users in Montreal? J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S57-9.
26. Bruneau J, Lamothe F, Franco E, et al. High rates of HlV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol 1997;146:994-1002.
27. Valleroy LA, Weinstein B, Jones TS, et al. Impact of increased legal access to needles and syringes on community pharmacies' needle and syringe sales - Connecticut, 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:73-81.
28. Groseclose SL, Weinstein B, Jones TS, et al. Impact of increased legal access to needles and syringes on the practices of injecting-drug users and police officers - Connecticut, 1992-93. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:82-9.
29. Diaz T, Chu SY, Weinstein B, Mokotoff E, Jones TS, et al. Injection and syringe sharing among HIV-infected injectors: implications for prevention of HIV transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S76-81.
30. Wright-De Agüero L, Weinstein B, Jones TS, Miles J. The impact of the change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers' practices. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S102-10.
31. Gleghorn, AA, Gee G, Vlahov D. Pharmacists' attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S89-93.
32. Beckett GA, Galena R, Shields D, Mills DA. Maine removed criminal penalties for syringe possession in 1997 after allowing sale of syringes without a prescription in 1993 [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S145-6.
33. Case P, Beckett GA, Jones TS. Access to sterile syringes in Maine: pharmacy practice after the 1993 repeal of the syringe prescription law. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S94-101.
34. Wright LN, Gebbie KM. Oregon's exclusion of syringes from its 1987 drug paraphernalia law was an HIV prevention measure [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S144-5.
35. Weinstein B, Toce P, Katz D, Ryan LL. Peer education of pharmacists and supplying pharmacies with IDU packets to increase injection drug users' access to sterile syringes in Connecticut [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S146-7.
36. Macalino GE, Springer KW, Rahman ZS, Vlahov D, Jones TS. Community-based programs for safe disposal of used needles and syringes. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S111-9.
37. Riley E, Beilenson P, Vlahov D, et al. Operation Red Box: a pilot project of needle and syringe drop boxes for injection drug users in East Baltimore. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S120-5.
38. Lurie P, Gorsky R, Jones TS, Shomphe L. An economic analysis of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S45-51.
39. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S133-8.
40. Lundberg GD. New winds blowing for American drug policies [editorial]. JAMA 1997;278:946-7.